

- G 150 R*
1. (Amended) A method for non-alimentary nutrition comprising administering by a parenteral route to a non-diabetic patient in need of parenteral nutrition, a [pharmaceutical] nutrient composition comprising a source of water soluble carbohydrate nutrients and one or more insulinotropic peptides at a standardized concentration.
 2. The [A] method [according to] of claim 1 wherein the source of carbohydrate nutrients [is a source of carbohydrates] directly or indirectly yields glucose when taken up by the body.

Please add the following new claims:

- G 2*
17. The method of claim 2 wherein the source of carbohydrate nutrients is a hexose, pentose, hexose alcohol, pentose alcohol, or any combination thereof.
 18. The method of claim 3 wherein the source of carbohydrate nutrients is glucose, fructose, galactose, xylitol, mannitol, sorbitol, or any combination thereof.
 19. The method of claim 1 wherein the source of carbohydrate nutrients is one or more assimilable amino acids, lipids, free fatty acids, mono- or diglycerides or glycerol.
 20. The method of claim 2 wherein the administration of the source of carbohydrate nutrients to the patient produces a blood glucose level in the patient of no more than from about 80 to 180 mg glucose per deciliter of blood and the rate of administration of the source of carbohydrate nutrients is calculated to deliver up to about 1000 g of glucose or its equivalent per patient per day.
 21. The method of claim 1 wherein the administration of the insulinotropic peptide or peptides produces a blood level of the peptide or peptides in the range of 1 pmol per L to 1 mmol per L of blood plasma.

22. The method of claim 1 wherein the insulinotropic peptide is GLP-1, GIP, GLP-1 (7-34), GLP-1 (7-35), GLP-1 (7-36), GLP (7-37), the deletion sequences thereof, the natural and non-natural amino acid residue substitutes thereof, the C-terminus carboxamides thereof, the C-terminus esters thereof, the D-terminus ketones thereof, the N-terminus modifications thereof or any mixture thereof.
23. The method of claim 2 wherein the nutrient composition comprises a source of carbohydrate in a first aqueous medium and one or more insulinotropic peptides in a second aqueous medium or a pharmaceutically acceptable solid or gel tab or sustained release matrix.
24. The method of claim 1 wherein the standardized concentration of insulinotropic peptide or peptides being administered is sufficient to provide a plateau level of the insulinotropic peptide or peptides in the patient's blood.
25. The method of claim 1 wherein the nutrients and insulinotropic peptide or peptides are continuously and coterminally administered.
26. A nutrient composition comprising a source of carbohydrate nutrients and one or more insulinotropic peptides in an amount calculated to provide a standardized concentration of insulinotropic peptide or peptides when administered to a patient, wherein the nutrients and peptide or peptides are in separate or combined form.
27. The nutrient composition of claim 26 wherein the source of carbohydrate nutrient directly or indirectly yields glucose when taken up by the body.
28. The nutrient composition of claim 27 wherein the source of carbohydrate nutrient is present at a concentration of about 2% to about 50% by weight of glucose or its equivalent per L.
29. The nutrient composition of claim 26 wherein the insulinotropic peptide or peptides are present at a concentration of about 1 nmol per L to about 1 mmol per L.